Open Label Pilot Study of 2% Tofacitinib for the Treatment of Refractory Vitiligo.
Open Label Pilot Study of 2% Tofacitinib for the Treatment of Refractory Vitiligo.
Br J Dermatol. 2019 Oct 12;:
Authors: Mobasher P, Guerra R, Jiayang Li S, Frangos J, Ganesan AK, Huang V
Abstract
Treatment options for vitiligo are limited and many cases remain refractory to first and second line treatments. Interferon-gamma signaling mediated by Janus kinase (JAK) has been implicated in the pathogenesis of vitiligo.1 Systemic administration of tofacitinib, a potent JAK1/3 inhibitor, has been effective in treating vitiligo in case reports,2 however, it is associated with infections, malignancies, cytopenias, gastrointestinal perforations, and hyperlipidemia in some patients with rheumatoid arthritis.
PMID: 31605536 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Mobasher P, Guerra R, Jiayang Li S, Frangos J, Ganesan AK, Huang V Tags: Br J Dermatol Source Type: research
More News: Arthritis | Cancer & Oncology | Dermatology | Gastroenterology | Rheumatoid Arthritis | Rheumatology | Skin | Study | UK Health | Vitiligo